Today’s Stock Ideas
💡 Want more than just today’s 3 stock ideas?
Right now you’re only seeing a taste. Our full database has hundreds of stock ideas pulled straight from the smartest investors and podcasts every week.
Unlock full access today for just $1 for 3 days (then $10/month)
1. RGTI Bounceback Buy Zone
"RGTI is currently seeing a take-profit cycle after a nice JP Morgan driven pump of quantum assets. These risk on stocks often see floors start falling out during take-profit cycles before bottoming and reversing. We are expecting 32 to $42 to be a bounceback range and ideal buy zone before the rebound to a new high."
ZipTrader
The speaker provides an explicit trade call for RGTI, indicating a potential buying opportunity in the bounceback range of $32 to $42 following a take-profit cycle, supported by momentum from a JP Morgan-driven quantum pump.
2. Trade Call: Buy CURE on Attractive Valuation from Potential Buyout
"Well, my price target, what would be your price target for Cure in case of a buyout conservatively? That is our question, right? Cure is not a cure for Huntington's to be clear. It is a treatment, a potential treatment without definitive control data, making it speculative. Drug companies don’t buy companies for fun; they do it to secure a deal. And then they say, "What’s the price?" Oh, it’s only 77 market cap. I’ll buy that, and I’d buy that all the way up to a billion. That’s how you do finance."
The Shkreli Pill
The speaker outlines a valuation-based trade idea for Cure, emphasizing that despite its speculative nature, if a drug company were to acquire the firm at only a 77 market cap, the stock is so undervalued that he would buy it aggressively—even up to a valuation of a billion. The insight underscores a fundamental finance approach by focusing on underlying asset value rather than the current stock price.
3. ABAT Overreaction on Grant Pull Presents Buy Opportunity
"American Battery Technology Corp., ticker symbol ABAT. While ABAT is a US-based firm building a vertically integrated lithium supply chain, the company saw a big sell-off after the DOE pulled a $57 million grant for its Reno based lithium project. I would argue that whatever the sell-off is if it continues this week or if it bottoms this week, the overall bigger picture is that it's a complete overreaction. I think this is going to change absolutely nothing for the company, and once it bottoms, ABAT has a lot of potential due to strong domestic lithium demand."
ZipTrader
The speaker contends that ABAT’s significant sell-off following a $57 million grant pull is an overreaction. He believes that, once the stock bottoms, the company’s strong domestic lithium focus will drive long-term value, presenting a potential buying opportunity.